Share class: INVO Bioscience, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A13,906,0723,881,475 ( 99.37 %) 0 99.37 %

Major shareholders: INVO Bioscience, Inc.

NameEquities%Valuation
Vanguard Group, Inc. (Subfiler)
1.384 %
54,058 1.384 % 43 300 $
Geode Capital Management LLC
0.8350 %
32,614 0.8350 % 26 124 $
Two Sigma Securities LLC
0.4088 %
15,968 0.4088 % 12 790 $
Virtu Financial LLC
0.3177 %
12,409 0.3177 % 9 940 $
7,804 0.1998 % 6 251 $
Steven Shum
0.1685 %
6,581 0.1685 % 5 271 $
Tower Research Capital LLC
0.1307 %
5,106 0.1307 % 4 090 $
3,840 0.0983 % 3 076 $
1,960 0.0502 % 1 570 $
Trent Davis
0.0431 %
1,682 0.0431 % 1 347 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Other1.70%
Institutional1.41%
Individuals0.63%
Unknown96.26%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 3.11%
Individuals 0.63%

Based on 1000 largest holdings

Logo INVO Bioscience, Inc.
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
Employees
28
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW